激素疗法与乳腺癌风险：我们目前的状况如何？
Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
作者信息
Micha John P, Rettenmaier Mark A, Bohart Randy D, Goldstein Bram H
机构信息
Women's Cancer Research Foundation, Laguna Beach, CA, USA.
Oso Home Care, Inc., Irvine, CA, USA.
出版信息
J Menopausal Med. 2022 Aug;28(2):47-51. doi: 10.6118/jmm.21035.
Abstract
Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. Hence, physicians and nurses should actively engage in constructive discourse with their patients regarding HRT while specifically reviewing the potential risks of its extended use as well as provide the available medical alternatives the patients could potentially use.
摘要
多项研究探讨了激素替代疗法（HRT）的临床益处。然而，由于长期使用HRT被认为是乳腺癌发生的一个风险因素，一些女性在考虑用这种疗法来缓解她们的血管舒缩症状时仍持怀疑态度。因此，医生和护士应积极与患者就HRT展开建设性的讨论，特别要审视其长期使用的潜在风险，并提供患者可能使用的现有医疗替代方案。
相似文献
1
Hormone Therapy and Risk of Breast Cancer: Where Are We Now?激素疗法与乳腺癌风险：我们目前的状况如何？
J Menopausal Med. 2022 Aug;28(2):47-51. doi: 10.6118/jmm.21035.
2
Hormone replacement therapy and breast cancer: revisiting the issues.激素替代疗法与乳腺癌：重新审视相关问题
J Am Pharm Assoc (Wash). 1998 Nov-Dec;38(6):738-44; quiz 744-6. doi: 10.1016/s1086-5802(16)30395-3.
3
Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.癌症幸存者的激素替代疗法——文献综述。
Pathol Oncol Res. 2020 Jan;26(1):63-78. doi: 10.1007/s12253-018-00569-x. Epub 2019 Jan 8.
4
ACOG committee opinion. Risk of breast cancer with estrogen-progestin replacement therapy.美国妇产科医师学会委员会意见。雌激素 - 孕激素替代疗法与乳腺癌风险
Int J Gynaecol Obstet. 2002 Mar;76(3):333-5. doi: 10.1016/s0020-7292(02)90019-6.
5
Benefits of hormone replacement therapy in postmenopausal women.绝经后女性激素替代疗法的益处。
J Am Acad Nurse Pract. 2007 Dec;19(12):635-41. doi: 10.1111/j.1745-7599.2007.00269.x.
6
Hormone replacement therapy and cancer.激素替代疗法与癌症。
Gynecol Endocrinol. 2001 Dec;15(6):453-65.
7
8
Committee opinion: number 262, December 2001. Risk of breast cancer with estrogen-progestin replacement therapy.委员会意见：第262号，2001年12月。雌激素 - 孕激素替代疗法与乳腺癌风险
Obstet Gynecol. 2001 Dec;98(6):1181-4. doi: 10.1016/s0029-7844(01)01705-7.
9
10
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.激素替代疗法对乳腺癌风险的影响：雌激素与雌激素加孕激素对比
J Natl Cancer Inst. 2000 Feb 16;92(4):328-32. doi: 10.1093/jnci/92.4.328.
引用本文的文献
1
Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.安大略省医疗保险计划中女性癌症诊断计费率在新冠疫情期间的变化。
Ther Adv Med Oncol. 2025 May 26;17:17588359251339919. doi: 10.1177/17588359251339919. eCollection 2025.
2
Comprehensive Analysis of Receptor Status, Histopathological Classifications (B1-B5), and Cumulative Histological Dimensions in Breast Cancer: Predictors of Malignancy and Diagnostic Implications.乳腺癌中受体状态、组织病理学分类（B1-B5）及累积组织学维度的综合分析：恶性肿瘤的预测因素及诊断意义
Cancers (Basel). 2024 Oct 14;16(20):3471. doi: 10.3390/cancers16203471.
3
A Recent Review of the Management of Postmenopausal Symptoms in Breast Cancer Survivors.乳腺癌幸存者绝经后症状管理的近期综述
J Menopausal Med. 2023 Dec;29(3):85-91. doi: 10.6118/jmm.23016.
本文引用的文献
1
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
2
Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.激素替代疗法的使用与乳腺癌风险：使用 QResearch 和 CPRD 数据库的巢式病例对照研究。
BMJ. 2020 Oct 28;371:m3873. doi: 10.1136/bmj.m3873.
3
Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.BRCA1/BRCA2 基因突变患者降低风险手术后的激素治疗：潜在益处与安全性评估
Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.
4
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.绝经激素治疗的类型和时机与乳腺癌风险：全球流行病学证据的个体参与者荟萃分析。
Lancet. 2019 Sep 28;394(10204):1159-1168. doi: 10.1016/S0140-6736(19)31709-X. Epub 2019 Aug 29.
5
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.预防性降低风险的输卵管卵巢切除术（RRSO）后激素替代疗法与 BRCA1 和 BRCA2 突变携带者乳腺癌风险：一项荟萃分析。
Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3.
6
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.绝经激素治疗与全因及特定病因长期死亡率：妇女健康倡议随机试验
JAMA. 2017 Sep 12;318(10):927-938. doi: 10.1001/jama.2017.11217.
7
The 2017 hormone therapy position statement of The North American Menopause Society.北美更年期协会2017年激素治疗立场声明。
Menopause. 2017 Jul;24(7):728-753. doi: 10.1097/GME.0000000000000921.
8
Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.植物疗法与更年期症状：系统评价与荟萃分析。
JAMA. 2016 Jun 21;315(23):2554-63. doi: 10.1001/jama.2016.8012.
9
Impact of progesterone on stem/progenitor cells in the human breast.孕酮对人乳腺中干细胞/祖细胞的影响。
J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):27-37. doi: 10.1007/s10911-015-9339-y. Epub 2015 Aug 8.
10
Critical appraisal of paroxetine for the treatment of vasomotor symptoms.对帕罗西汀治疗血管舒缩症状的批判性评价。
Int J Womens Health. 2015 Jun 18;7:615-24. doi: 10.2147/IJWH.S50804. eCollection 2015.
Zotero 插件